Development of a VesiVax® HIV Vaccine Formulation
Award Notice Posted
- Solicitation number
- PHS2021-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Molecular Express, Inc.
- Set-aside
- Total Small Business
Opportunity facts
- Contract number
- 75N93021C00027 Federal contract award
- Place of performance
- Rancho Dominguez, California 90220, United States
Notice details come from SAM.gov. Updated .
About this opportunity
Molecular Express Inc. was awarded a $2,294,565 contract by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to develop a VesiVax HIV vaccine formulation intended to help prevent the transmission and progression of HIV/AIDS through 2023. This total small business set aside contract supports the contractor's work advancing the development of a vaccine to address this important public health issue by developing a VesiVax HIV vaccine formulation by 2023.
Notice text
Awarded contract 75N93021C00027 to Molecular Express Inc for 2294565.00 on 2021-07-01.
Notice history
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity